<DOC>
	<DOCNO>NCT02201524</DOCNO>
	<brief_summary>Study B7451005 Phase 2 study ass efficacy safety PF-04965842 patient moderate severe psoriasis . The study include three PF-04965842 group ( 200 mg daily , 400 mg daily 200 mg twice daily ) placebo group . The treatment period 4 week duration follow 4 week follow period .</brief_summary>
	<brief_title>Study Evaluate PF-04965842 Patients With Moderate Severe Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . Have diagnosis plaque psoriasis least 6 month prior first study dose . 2 . Have plaque type psoriasis cover least 15 % total BSA Day 1 ( time first study dose ) . 3 . Have PASI score 12 great Day 1 ( time first study dose ) . 4 . Be candidate phototherapy systemic treatment psoriasis ( either naïve history previous treatment ) . 1 . Currently non plaque form psoriasis , eg , erythrodermic , guttate , pustular psoriasis . 2 . 3 . Have current drug induce psoriasis , eg , new onset psoriasis exacerbation psoriasis beta blocker , calcium channel blocker , antimalarial drug lithium . 3 . Have receive following treatment regimen specify timeframes outline : Within 9 month first dose study drug : • Ustekinumab ( Stelara ) . Within 12 week first dose study drug : • Any experimental therapy psoriasis rheumatoid arthritis . Within 4 8 week first dose study drug : Biologic therapy psoriasis discontinuation period determine approximately 5x half life respective biologic : 4 week : etanercept ( Enbrel ) . 8 week : infliximab ( Remicade ) , adalimumab ( Humira ) . Within 4 week first dose study drug : Systemic treatment biologics could affect psoriasis ( eg , oral injectable corticosteroid , retinoids , methotrexate , cyclosporine , fumaric acid derivative , sulfasalazine , hydroxycarbamide ( hydroxyurea ) , azathioprine ) . Phototherapy psoralen plus ultraviolet A therapy ( PUVA ) . Other intramuscular gold , immunization live virus vaccination ( eg , FluMist ) , herbal medication . Within 2 week first dose study drug : Topical treatment could affect psoriasis ( eg , corticosteroid , tar , keratolytics , anthralin , vitamin D analog , retinoids ) . Phototherapy ultraviolet B ( UVB ) ( narrowband broadband ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Phase 2</keyword>
	<keyword>randomize</keyword>
	<keyword>double-blind</keyword>
	<keyword>placebo</keyword>
	<keyword>plaque</keyword>
	<keyword>psoriasis</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>JAK</keyword>
	<keyword>janus kinase</keyword>
	<keyword>moderate</keyword>
	<keyword>severe</keyword>
</DOC>